Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SIGMAR1 | Q99720 | 3/20 | 0.56 |
| ▸ | ADRA2A | P08913 | 14/20 | 0.44 |
| ▸ | ADRA2B | P18089 | 14/20 | 0.44 |
| ▸ | ADRA2C | P18825 | 14/20 | 0.44 |
| ▸ | ADRA1A | P35348 | 14/20 | 0.44 |
| ▸ | HTR1A | P08908 | 1/20 | 0.41 |
| ▸ | DRD2 | P14416 | 1/20 | 0.41 |
| ▸ | HTR2A | P28223 | 1/20 | 0.41 |
| ▸ | HTR7 | P34969 | 1/20 | 0.41 |
| ▸ | HRH1 | P35367 | 1/20 | 0.41 |
| ▸ | DRD3 | P35462 | 1/20 | 0.41 |
| ▸ | HTR2B | P41595 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL4471883 | 0.99 | SIGMAR1 (0.55) | SIGMAR1ADRA2AADRA2BADRA2CADRA1A | |
| SCHEMBL4477169 | 0.92 | SIGMAR1 (0.54) | SIGMAR1ADRA2AADRA2BADRA2CADRA1A | |
| SCHEMBL4473668 | 0.90 | SIGMAR1 (0.52) | SIGMAR1ADRA2AADRA2BADRA2CADRA1A | |
| SCHEMBL4473364 | 0.82 | SIGMAR1 (0.56) | SIGMAR1ADRA2AADRA2BADRA2CADRA1A | |
| SCHEMBL7147206 | 0.81 | DRD2 (0.65) | SIGMAR1HTR1ADRD2HTR2AHTR7 | |
| SCHEMBL7143960 | 0.79 | HTR1A (0.60) | SIGMAR1HTR1ADRD2HTR2AHTR7 | |
| SCHEMBL4473156 | 0.75 | SIGMAR1 (0.61) | SIGMAR1ADRA2AADRA2BADRA2CADRA1A | |
| SCHEMBL6869743 | 0.74 | SIGMAR1 (0.62) | SIGMAR1ADRA2AADRA2BADRA2CADRA1A | |
| SCHEMBL20502157 | 0.73 | SIGMAR1 (1.00) | SIGMAR1ADRA2AADRA2BADRA2CADRA1A | |
| SCHEMBL22528282 | 0.73 | SIGMAR1 (0.80) | SIGMAR1ADRA2AADRA2BADRA2CADRA1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7601734-B2 | Such as methyl 5-(3,4-dihydro[1]benzofuro[3,2-c]pyridine-2(1H)-yl)-2,2-bis(4-fluorophenyl)pentanoate, having potent inhibitory effect on binding of alpha 2C-adrenoceptor; depression, anxiety, schizophrenia | TAISHO PHARMACEUTICAL CO., LTD. (JP) | 2009-10-13 | — | — | US | disclosed |
| US-7601734-B2 | Such as methyl 5-(3,4-dihydro[1]benzofuro[3,2-c]pyridine-2(1H)-yl)-2,2-bis(4-fluorophenyl)pentanoate, having potent inhibitory effect on binding of alpha 2C-adrenoceptor; depression, anxiety, schizophrenia | TAISHO PHARMACEUTICAL CO., LTD. (JP) | 2009-10-13 | — | — | US | disclosed |
| US-7601734-B2 | Such as methyl 5-(3,4-dihydro[1]benzofuro[3,2-c]pyridine-2(1H)-yl)-2,2-bis(4-fluorophenyl)pentanoate, having potent inhibitory effect on binding of alpha 2C-adrenoceptor; depression, anxiety, schizophrenia | TAISHO PHARMACEUTICAL CO., LTD. (JP) | 2009-10-13 | — | — | US | disclosed |
| US-20070244145-A1 | Cyclic Amine Compound | TAISHO PHARMACEUTICAL CO., LTD. (JP) | 2007-10-18 | — | — | US | disclosed |
| US-20070244145-A1 | Cyclic Amine Compound | TAISHO PHARMACEUTICAL CO., LTD. (JP) | 2007-10-18 | — | — | US | disclosed |
| US-20070244145-A1 | Cyclic Amine Compound | TAISHO PHARMACEUTICAL CO., LTD. (JP) | 2007-10-18 | — | — | US | disclosed |
| EP-1757605-A1 | CYCLIC AMINE COMPOUND | TAISHO PHARMACEUTICAL CO., LTD (JP) | 2007-02-28 | — | — | EP | disclosed |
| EP-1757605-A1 | CYCLIC AMINE COMPOUND | TAISHO PHARMACEUTICAL CO., LTD (JP) | 2007-02-28 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070244145-A1 | Cyclic Amine Compound | ADRA2C, ADRB2, NR2C2 | SIGMAR1 148/4885ADRA2A 4/4885ADRA2B 6/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.